...
首页> 外文期刊>Clinical transplantation. >Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation.
【24h】

Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation.

机译:钙调神经磷酸酶抑制剂治疗的中止使肾脏移植后患者体内产生了FOXP3 +调节性T细胞。

获取原文
获取原文并翻译 | 示例

摘要

This study investigated specific gene expression profiles in patients with donor-specific cytotoxic-hyporesponsiveness, reflected by cytotoxic T-lymphocyte precursor frequency (CTLpf). The effect of calcineurin inhibitor (CNI) withdrawal was studied on markers for cytotoxicity (perforin, granzyme B), apoptosis (Fas,FasL), Th1 and Th2 cytokines (IL-2, IL-10), Th1 and Th2 transcription factors (T-bet, GATA 3), Th17 transcription factor and cytokine (RORgammat, IL-17), and for immune regulation/activation (CD25, FOXP3). Peripheral blood samples from renal allograft recipients (n = 18) more than two yr after transplantation with stable renal function were analyzed before and four months after CNI withdrawal. Additionally, systolic and diastolic blood pressure, cholesterol, serum creatinine and proteinuria were evaluated, and no significant differences were measured before and after CNI withdrawal. However, CNIs' discontinuation influenced peripheral gene expression profiles. After CNI withdrawal, the mRNA expression of Granzyme B, Perforin, Fas, FasL, T-bet, GATA3 and CD25 were significantly lower than during CNI treatment. After CNI discontinuation, donor-specific CTLpf decreased, while FOXP3 expression discriminated between detectable and non-detectable donor-specific cytolysis reactivity; FOXP3 transcript values were highest in absence of donor-specific cytotoxicity (p < 0.01). Our study shows CNI withdrawal in stable kidney transplant recipients two yr after transplantation is safe. Moreover, discontinuation of CNIs' treatment allows FOXP3+ regulatory T-cells development, resulting in a significant decrease of anti-donor immune reactivity.
机译:这项研究调查了具有供体特异性细胞毒性低反应性的患者中的特定基因表达谱,通过细胞毒性T淋巴细胞前体频率(CTLpf)反映出来。研究了钙调神经磷酸酶抑制剂(CNI)撤药对细胞毒性(穿孔素,颗粒酶B),凋亡(Fas,FasL),Th1和Th2细胞因子(IL-2,IL-10),Th1和Th2转录因子(T -bet,GATA 3),Th17转录因子和细胞因子(RORgammat,IL-17),以及用于免疫调节/激活(CD25,FOXP3)。在撤离CNI之前和之后四个月,对移植了两年以上且肾功能稳定的肾同种异体移植受者(n = 18)的外周血进行了分析。此外,评估了收缩压和舒张压,胆固醇,血清肌酐和蛋白尿,在退出CNI之前和之后均未观察到显着差异。但是,CNIs的中断影响了外周基因表达谱。退出CNI后,颗粒酶B,穿孔素,Fas,FasL,T-bet,GATA3和CD25的mRNA表达均显着低于CNI治疗期间。 CNI停用后,供体特异性CTLpf降低,而FOXP3表达则可检测到和不可检测供体特异性细胞溶解反应。在没有供体特异性细胞毒性的情况下,FOXP3转录物值最高(p <0.01)。我们的研究表明,在移植两年后,在稳定的肾脏移植受者中退出CNI是安全的。此外,CNIs治疗的中止使FOXP3 +调节性T细胞得以发展,导致抗供体免疫反应性显着降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号